Search

Your search keyword '"Polyzogopoulou, Eftihia"' showing total 42 results
Start Over Author "Polyzogopoulou, Eftihia" Publication Year Range Last 50 years
42 results on '"Polyzogopoulou, Eftihia"'

2. Impaired Endothelial Glycocalyx Predicts Adverse Outcome in Subjects Without Overt Cardiovascular Disease: a 6-Year Follow-up Study

Author

Ikonomidis, Ignatios, Thymis, John, Simitsis, Panagiotis, Koliou, Georgia-Angeliki, Katsanos, Spiridon, Triantafyllou, Charilaos, Kousathana, Foteini, Pavlidis, George, Kountouri, Aikaterini, Polyzogopoulou, Eftihia, Katogiannis, Konstantinos, Vlastos, Dimitrios, Kostelli, Gavriella, Triantafyllidi, Helen, Parissis, John, Papadavid, Evangelia, Lekakis, John, Filippatos, Gerasimos, and Lambadiari, Vaia

Published
2022
Full Text
View/download PDF

5. Prognostic Role of Soluble Urokinase Plasminogen Activator Receptor at the Emergency Department: A Position Paper by the Hellenic Sepsis Study Group

Author

Velissaris, Dimitrios, Dimopoulos, George, Parissis, John, Alexiou, Zoi, Antonakos, Nikolaos, Babalis, Dimitrios, Gerakari, Styliani, Kaldis, Vassileios, Koutoukas, Pantelis, Lada, Malvina, Leventogiannis, Konstantinos, Pantazopoulos, Ioannis, Papadopoulos, Antonios, Polyzogopoulou, Eftihia, Gogos, Charalambos, Armaganidis, Apostolos, and Giamarellos-Bourboulis, Evangelos J.

Published
2020
Full Text
View/download PDF

8. Impact of left ventricular ejection fraction phenotypes on healthcare resource utilization in hospitalized heart failure: a secondary analysis of REPORT‐HF

Author

Farmakis, Dimitrios, primary, Tromp, Jasper, additional, Marinaki, Smaragdi, additional, Ouwerkerk, Wouter, additional, Angermann, Christiane E., additional, Bistola, Vasiliki, additional, Dahlstrom, Ulf, additional, Dickstein, Kenneth, additional, Ertl, Georg, additional, Ghadanfar, Mathieu, additional, Hassanein, Mahmoud, additional, Obergfell, Achim, additional, Perrone, Sergio V., additional, Polyzogopoulou, Eftihia, additional, Schweizer, Anja, additional, Boletis, Ioannis, additional, Cleland, John G.F., additional, Collins, Sean P., additional, Lam, Carolyn S.P., additional, and Filippatos, Gerasimos, additional

Published
2023
Full Text
View/download PDF

9. Impact of left ventricular ejection fraction phenotypes on healthcare resource utilization in hospitalized heart failure: a secondary analysis of REPORT-HF

Author

Farmakis, Dimitrios, Tromp, Jasper, Marinaki, Smaragdi, Ouwerkerk, Wouter, Angermann, Christiane E. E., Bistola, Vasiliki, Dahlström, Ulf, Dickstein, Kenneth, Ertl, Georg, Ghadanfar, Mathieu, Hassanein, Mahmoud, Obergfell, Achim, Perrone, Sergio V. V., Polyzogopoulou, Eftihia, Schweizer, Anja, Boletis, Ioannis, Cleland, John G. F., Collins, Sean P. P., Lam, Carolyn S. P., Filippatos, Gerasimos, Farmakis, Dimitrios, Tromp, Jasper, Marinaki, Smaragdi, Ouwerkerk, Wouter, Angermann, Christiane E. E., Bistola, Vasiliki, Dahlström, Ulf, Dickstein, Kenneth, Ertl, Georg, Ghadanfar, Mathieu, Hassanein, Mahmoud, Obergfell, Achim, Perrone, Sergio V. V., Polyzogopoulou, Eftihia, Schweizer, Anja, Boletis, Ioannis, Cleland, John G. F., Collins, Sean P. P., Lam, Carolyn S. P., and Filippatos, Gerasimos

Abstract

Aim Evidence on healthcare resource utilization (HCRU) for hospitalized patients with heart failure (HF) and reduced (HFrEF), mildly reduced (HFmrEF) and preserved (HFpEF) ejection fraction is limited.Methods and results We analysed HCRU in relation to left ventricular ejection fraction (LVEF) phenotypes, clinical features and in-hospital and 12-month outcomes in 16 943 patients hospitalized for HF in a worldwide registry. HFrEF was more prevalent (53%) than HFmrEF (17%) or HFpEF (30%). Patients with HFmrEF and HFpEF were older, more often women, with milder symptoms and more comorbidities, but differences were not pronounced. HCRU was high in all three groups; two or more in- and out-of-hospital services were required by 51%, 49% and 52% of patients with HFrEF, HFmrEF and HFpEF, respectively, and intensive care unit by 41%, 41% and 37%, respectively. Hospitalization length was similar (median, 8 days). Discharge prescription of neurohormonal inhibitors was <80% for each agent in HFrEF and only slightly lower in HFmrEF and HFpEF (74% and 67%, respectively, for beta-blockers). Compared to HFrEF, 12-month all-cause and cardiovascular mortality were lower for HFmrEF (adjusted hazard ratios 0.78 [95% confidence interval 0.59-0.71] and 0.80 [0.70-0.92]) and HFpEF (0.64 [0.59-0.87] and 0.63 [0.56-0.71]); 12-month HF hospitalization was also lower for HFpEF and HFmrEF (21% and 20% vs. 25% for HFrEF). In-hospital mortality, 12-month non-cardiovascular mortality and 12-month all-cause hospitalization were similar among groups.Conclusions In patients hospitalized for HF, overall HCRU was similarly high across LVEF spectrum, reflecting the subtle clinical differences among LVEF phenotypes during hospitalization. Discharge prescription of neurohormonal inhibitors was suboptimal in HFrEF and lower but significant in patients with HFpEF and HFmrEF, who had better long-term cardiovascular outcomes than HFrEF, but similar risk for non-cardiovascular events., Funding Agencies|Novartis Pharma AG

Published
2023
Full Text
View/download PDF

10. Impact of left ventricular ejection fraction phenotypes on healthcare resource utilization in hospitalized heart failure: a secondary analysis of <scp>REPORT‐HF</scp>

Author

Farmakis, Dimitrios, Tromp, Jasper, Marinaki, Smaragdi, Ouwerkerk, Wouter, Angermann, Christiane E, Bistola, Vasiliki, Dahlstrom, Ulf, Dickstein, Kenneth, Ertl, Georg, Ghadanfar, Mathieu, Hassanein, Mahmoud, Obergfell, Achim, Perrone, Sergio V, Polyzogopoulou, Eftihia, Schweizer, Anja, Boletis, Ioannis, Cleland, John Gf, Collins, Sean P, Lam, Carolyn Sp, FIlippatos, Gerasimos, Epidemiology and Data Science, CCA - Cancer Treatment and Quality of Life, CCA - Imaging and biomarkers, CCA - Cancer biology and immunology, and AII - Cancer immunology

Subjects
Left ventricular ejection fraction, Heart failure, Mortality, Heart failure hospitalization, Prognosis, Cardiology and Cardiovascular Medicine, Pharmacotherapy
Abstract

Aim: Evidence on healthcare resource utilization (HCRU) for hospitalized patients with heart failure (HF) and reduced (HFrEF), mildly reduced (HFmrEF) and preserved (HFpEF) ejection fraction is limited. Methods and results: We analysed HCRU in relation to left ventricular ejection fraction (LVEF) phenotypes, clinical features and in-hospital and 12-month outcomes in 16 943 patients hospitalized for HF in a worldwide registry. HFrEF was more prevalent (53%) than HFmrEF (17%) or HFpEF (30%). Patients with HFmrEF and HFpEF were older, more often women, with milder symptoms and more comorbidities, but differences were not pronounced. HCRU was high in all three groups; two or more in- and out-of-hospital services were required by 51%, 49% and 52% of patients with HFrEF, HFmrEF and HFpEF, respectively, and intensive care unit by 41%, 41% and 37%, respectively. Hospitalization length was similar (median, 8 days). Discharge prescription of neurohormonal inhibitors was

Published
2023
Full Text
View/download PDF

11. Optimal use of intravenous landiolol in acute cardiac care.

Author

Bezati, Sofia, Boultadakis, Antonios, Ventoulis, Ioannis, Polyzogopoulou, Eftihia, and Parissis, John T.

Subjects
VENTRICULAR tachycardia, HEART diseases, MYOCARDIAL infarction, CARDIAC patients, MEDICAL research, CARDIAC intensive care
Abstract

B-blockers are regarded as beneficial pharmacologic agents in cardiac care, but their role in the acute setting remains ambiguous. Increasing evidence supports the important role of landiolol in critical care, a highly cardioselective intravenous b-blocker with rapid onset of action and short elimination time. Among its most valuable properties, which may aid to overcome special reservations related to b-blocker therapy in the acute setting, landiolol has a potent negative chronotropic effect while at the same time it exhibits a mild negative inotropic effect. This expert opinion review aims to present basic pharmacologic aspects of landiolol and provide current clinical research focused on its efficacy and safety. Landiolol is a valuable and safe pharmacologic agent in acute cardiac care. Japanese and European guidelines have incorporated its use for the management of atrial tachyarrhythmia in patients with cardiac dysfunction. Although emerging clinical trials have experimented its use in patients with sustained ventricular tachycardia/fibrillation, acute myocardial infarction undergoing primary percutaneous intervention and in patients with septic cardiomyopathy, more studies are needed in order to establish its value in such cardiac conditions. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

12. Fagerstrom score predicts smoking status six months after hospitalization for acute myocardial infarction: a prospective study

Author

Ikonomidis, Ignatios, primary, Thymis, John, additional, Kourea, Kallirhoe, additional, Kostelli, Gavriella, additional, Neocleous, Antria, additional, Katogiannis, Konstantinos, additional, Makavos, George, additional, Polyzogopoulou, Eftihia, additional, Plotas, Panagiotis, additional, Lambadiari, Vaia, additional, and Parissis, John, additional

Published
2022
Full Text
View/download PDF

15. Impaired Endothelial Glycocalyx Predicts Adverse Outcome in Subjects Without Overt Cardiovascular Disease: a 6-Year Follow-up Study

Author

Ikonomidis, Ignatios, primary, Thymis, John, additional, Simitsis, Panagiotis, additional, Koliou, Georgia-Angeliki, additional, Katsanos, Spiridon, additional, Triantafyllou, Charilaos, additional, Kousathana, Foteini, additional, Pavlidis, George, additional, Kountouri, Aikaterini, additional, Polyzogopoulou, Eftihia, additional, Katogiannis, Konstantinos, additional, Vlastos, Dimitrios, additional, Kostelli, Gavriella, additional, Triantafyllidi, Helen, additional, Parissis, John, additional, Papadavid, Evangelia, additional, Lekakis, John, additional, Filippatos, Gerasimos, additional, and Lambadiari, Vaia, additional

Published
2021
Full Text
View/download PDF

16. Advanced Neuroimaging Preceding Intravenous Thrombolysis in Acute Ischemic Stroke Patients Is Safe and Effective

Author

Psychogios, Klearchos Safouris, Apostolos Kargiotis, Odysseas and Magoufis, Georgios Andrikopoulou, Athina Papageorgiou, Ermioni Chondrogianni, Maria Papadimitropoulos, Georgios and Polyzogopoulou, Eftihia Spiliopoulos, Stavros Brountzos, Elias and Stamboulis, Elefterios Giannopoulos, Sotirios Tsivgoulis, Georgios

Abstract

Advanced neuroimaging is one of the most important means that we have in the attempt to overcome time constraints and expand the use of intravenous thrombolysis (IVT). We assessed whether, and how, the prior use of advanced neuroimaging (AN), and more specifically CT/MR perfusion post-processed with RAPID software, regardless of time from symptoms onset, affected the outcomes of acute ischemic stroke (AIS) patients who received IVT. Methods. We retrospectively evaluated consecutive AIS patients who received intravenous thrombolysis monotherapy (without endovascular reperfusion) during a six-year period. The study population was divided into two groups according to the neuroimaging protocol used prior to IVT administration in AIS patients (AN+ vs. AN-). Safety outcomes included any intracranial hemorrhage (ICH) and 3-month mortality. Effectiveness outcomes included door-to-needle time, neurological status (NIHSS-score) on discharge, and functional status at three months assessed by the modified Rankin Scale (mRS). Results. The rate of IVT monotherapy increased from ten patients per year (n = 29) in the AN- to fifteen patients per year (n = 47) in the AN+ group. Although the onset-to-treatment time was longer in the AN+ cohort, the two groups did not differ in door-to-needle time, discharge NIHSS-score, symptomatic ICH, any ICH, 3-month favorable functional outcome (mRS-scores of 0-1), 3-month functional independence (mRS-scores of 0-2), distribution of 3-month mRS-scores, or 3-month mortality. Conclusion. Our pilot observational study showed that the incorporation of advanced neuroimaging in the acute stroke chain pathway in AIS patients increases the yield of IVT administration without affecting the effectiveness and safety of the treatment.

Published
2021

17. Advanced Neuroimaging Preceding Intravenous Thrombolysis in Acute Ischemic Stroke Patients Is Safe and Effective

Author

Psychogios, Klearchos, primary, Safouris, Apostolos, additional, Kargiotis, Odysseas, additional, Magoufis, Georgios, additional, Andrikopoulou, Athina, additional, Papageorgiou, Ermioni, additional, Chondrogianni, Maria, additional, Papadimitropoulos, Georgios, additional, Polyzogopoulou, Eftihia, additional, Spiliopoulos, Stavros, additional, Brountzos, Elias, additional, Stamboulis, Elefterios, additional, Giannopoulos, Sotirios, additional, and Tsivgoulis, Georgios, additional

Published
2021
Full Text
View/download PDF

18. Association between up‐titration of medical therapy and total hospitalizations and mortality in patients with recent worsening heart failure across the ejection fraction spectrum

Author

Bistola, Vasiliki, primary, Simitsis, Panagiotis, additional, Parissis, John, additional, Ouwerkerk, Wouter, additional, van Veldhuisen, Dirk J., additional, Cleland, John G., additional, Anker, Stefan D., additional, Samani, Nilesh J., additional, Metra, Marco, additional, Zannad, Faiez, additional, Polyzogopoulou, Eftihia, additional, Keramida, Kalliopi, additional, Farmakis, Dimitrios, additional, Voors, Adriaan A., additional, and Filippatos, Gerasimos, additional

Published
2021
Full Text
View/download PDF

20. Oral sucrosomial iron improves exercise capacity and quality of life in heart failure with reduced ejection fraction and iron deficiency: a non‐randomized, open‐label, proof‐of‐concept study

Author

Karavidas, Apostolos, primary, Troganis, Efstratios, additional, Lazaros, George, additional, Balta, Despina, additional, Karavidas, Ioannis‐Nektarios, additional, Polyzogopoulou, Eftihia, additional, Parissis, John, additional, and Farmakis, Dimitrios, additional

Published
2021
Full Text
View/download PDF

26. Safety and efficacy of salt substitution with a low sodium-potassium enriched dietary salt in patients with heart failure with reduced ejection fraction: A pilot study

Author

Bistola, Vasiliki, primary, Arfaras-Melainis, Angelos, additional, Trogkanis, Efstratios, additional, Bakosis, Georgios, additional, Polyzogopoulou, Eftihia, additional, Karavidas, Ioannis-Nektarios, additional, Ikonomidis, Ignatios, additional, Parissis, John, additional, and Karavidas, Apostolos, additional

Published
2020
Full Text
View/download PDF

28. Inotropes in Acute Heart Failure: From Guidelines to Practical Use: Therapeutic Options and Clinical Practice

Author

Bistola, Vasiliki Arfaras-Melainis, Angelos Polyzogopoulou, Eftihia Ikonomidis, Ignatios Parissis, John

Abstract

Inotropes are pharmacological agents that are indicated for the treatment of patients presenting with acute heart failure (AHF) with concomitant hypoperfusion due to decreased cardiac output. They are usually administered for a short period during the initial management of AHF until haemodynamic stabilisation and restoration of peripheral perfusion occur. They can be used for longer periods to support patients as a bridge to a more definite treatment, such as transplant of left ventricular assist devices, or as part of a palliative care regimen. The currently available inotropic agents in clinical practice fall into three main categories: beta-agonists, phosphodiesterase III inhibitors and calcium sensitisers. However, due to the well-documented potential for adverse events and their association with increased long-term mortality, physicians should be aware of the indications and dosing strategies suitable for different types of patients. Novel inotropes that use alternative intracellular pathways are under investigation, in an effort to minimise the drawbacks that conventional inotropes exhibit.

Published
2019

29. A pragmatic approach to the use of inotropes for the management of acute and advanced heart failure:An expert panel consensus

Author

Farmakis, Dimitrios, Agostoni, Piergiuseppe, Baholli, Loant, Bautin, Andrei, Comin-Colet, Josep, Crespo-Leiro, Maria G, Fedele, Francesco, García-Pinilla, Jose Manuel, Giannakoulas, George, Grigioni, Francesco, Gruchała, Marcin, Gustafsson, Finn, Harjola, Veli-Pekka, Hasin, Tal, Herpain, Antoine, Iliodromitis, Efstathios K, Karason, Kristjan, Kivikko, Matti, Liaudet, Lucas, Ljubas-Maček, Jana, Marini, Marco, Masip, Josep, Mebazaa, Alexandre, Nikolaou, Maria, Ostadal, Petr, Põder, Pentti, Pollesello, Piero, Polyzogopoulou, Eftihia, Pölzl, Gerhard, Tschope, Carsten, Varpula, Marjut, von Lewinski, Dirk, Vrtovec, Bojan, Yilmaz, Mehmet Birhan, Zima, Endre, Parissis, John, Farmakis, Dimitrios, Agostoni, Piergiuseppe, Baholli, Loant, Bautin, Andrei, Comin-Colet, Josep, Crespo-Leiro, Maria G, Fedele, Francesco, García-Pinilla, Jose Manuel, Giannakoulas, George, Grigioni, Francesco, Gruchała, Marcin, Gustafsson, Finn, Harjola, Veli-Pekka, Hasin, Tal, Herpain, Antoine, Iliodromitis, Efstathios K, Karason, Kristjan, Kivikko, Matti, Liaudet, Lucas, Ljubas-Maček, Jana, Marini, Marco, Masip, Josep, Mebazaa, Alexandre, Nikolaou, Maria, Ostadal, Petr, Põder, Pentti, Pollesello, Piero, Polyzogopoulou, Eftihia, Pölzl, Gerhard, Tschope, Carsten, Varpula, Marjut, von Lewinski, Dirk, Vrtovec, Bojan, Yilmaz, Mehmet Birhan, Zima, Endre, and Parissis, John

Abstract

Inotropes aim at increasing cardiac output by enhancing cardiac contractility. They constitute the third pharmacological pillar in the treatment of patients with decompensated heart failure, the other two being diuretics and vasodilators. Three classes of parenterally administered inotropes are currently indicated for decompensated heart failure, (i) the beta adrenergic agonists, including dopamine and dobutamine and also the catecholamines epinephrine and norepinephrine, (ii) the phosphodiesterase III inhibitor milrinone and (iii) the calcium sensitizer levosimendan. These three families of drugs share some pharmacologic traits, but differ profoundly in many of their pleiotropic effects. Identifying the patients in need of inotropic support and selecting the proper inotrope in each case remain challenging. The present consensus, derived by a panel meeting of experts from 21 countries, aims at addressing this very issue in the setting of both acute and advanced heart failure.

Published
2019

30. A pragmatic approach to the use of inotropes for the management of acute and advanced heart failure: an expert panel consensus

Author

Farmakis, Dimtrios, Agostoni, Piergiuseppe, Baholli, Loant, Bautin, Andrei, Comin-Colet, Josep, Crespo-Leiro, María Generosa, Fedele, Francesco, García-Pinilla, José Manuel, Giannakoulas, George, Grigioni, Francesco, Gruchała, Marcin, Gustafsson, Finn, Harjola, Veli-Pekka, Hasin, Tal, Herpain, Antoine, Iliodromitis, Efstathios K., Karason, Kristjan, Kivikko, Matti, Liaudet, Lucas, Ljubas-Maček, Jana, Marini, Marco, Masip, Josep, Mebazaa, Alexandre, Nikolaou, Maria, Ostadal, Petr, Põder, Pentti, Pollesello, Piero, Polyzogopoulou, Eftihia, Pölzl, Gerhard, Tschope, Carsten, Varpula, Marjut, Lewinski, Dirk von, Vrtovec, Bojan, Yilmaz, Mehmet Birhan, Zima, Endre, Parissis, John, Farmakis, Dimtrios, Agostoni, Piergiuseppe, Baholli, Loant, Bautin, Andrei, Comin-Colet, Josep, Crespo-Leiro, María Generosa, Fedele, Francesco, García-Pinilla, José Manuel, Giannakoulas, George, Grigioni, Francesco, Gruchała, Marcin, Gustafsson, Finn, Harjola, Veli-Pekka, Hasin, Tal, Herpain, Antoine, Iliodromitis, Efstathios K., Karason, Kristjan, Kivikko, Matti, Liaudet, Lucas, Ljubas-Maček, Jana, Marini, Marco, Masip, Josep, Mebazaa, Alexandre, Nikolaou, Maria, Ostadal, Petr, Põder, Pentti, Pollesello, Piero, Polyzogopoulou, Eftihia, Pölzl, Gerhard, Tschope, Carsten, Varpula, Marjut, Lewinski, Dirk von, Vrtovec, Bojan, Yilmaz, Mehmet Birhan, Zima, Endre, and Parissis, John

Abstract

[Abstract] Inotropes aim at increasing cardiac output by enhancing cardiac contractility. They constitute the third pharmacological pillar in the treatment of patients with decompensated heart failure, the other two being diuretics and vasodilators. Three classes of parenterally administered inotropes are currently indicated for decompensated heart failure, (i) the beta adrenergic agonists, including dopamine and dobutamine and also the catecholamines epinephrine and norepinephrine, (ii) the phosphodiesterase III inhibitor milrinone and (iii) the calcium sensitizer levosimendan. These three families of drugs share some pharmacologic traits, but differ profoundly in many of their pleiotropic effects. Identifying the patients in need of inotropic support and selecting the proper inotrope in each case remain challenging. The present consensus, derived by a panel meeting of experts from 21 countries, aims at addressing this very issue in the setting of both acute and advanced heart failure.

Published
2019

31. A pragmatic approach to the use of inotropes for the management of acute and advanced heart failure: An expert panel consensus

Author

Farmakis, Dimitrios, Agostoni, Piergiuseppe, Baholli, Loant, Bautin, Andrei, Comin-Colet, Josep, Crespo-Leiro, María Generosa, Fedele, Francesco, García-Pinilla, Jose Manuel, Giannakoulas, George, Grigioni, Francesco, Gruchała, Marcin, Gustafsson, Finn, Harjola, Veli Pekka, Hasin, Tal, Herpain, Antoine, Iliodromitis, Efstathios E.K., Karason, Kristjan, Kivikko, Matti, Liaudet, Lucas, Ljubas-Maček, Jana, Marini, Marco, Masip, Josep, Mebazaa, Alexandre, Nikolaou, Maria, Ostadal, Petr, Põder, Pentti, Pollesello, Piero, Polyzogopoulou, Eftihia, Pölzl, Gerhard, Tschope, Carsten, Varpula, Marjut, von Lewinski, Dirk, Vrtovec, Bojan, Yilmaz, Mehmet Birhan, Zima, Endre, Parissis, John, Farmakis, Dimitrios, Agostoni, Piergiuseppe, Baholli, Loant, Bautin, Andrei, Comin-Colet, Josep, Crespo-Leiro, María Generosa, Fedele, Francesco, García-Pinilla, Jose Manuel, Giannakoulas, George, Grigioni, Francesco, Gruchała, Marcin, Gustafsson, Finn, Harjola, Veli Pekka, Hasin, Tal, Herpain, Antoine, Iliodromitis, Efstathios E.K., Karason, Kristjan, Kivikko, Matti, Liaudet, Lucas, Ljubas-Maček, Jana, Marini, Marco, Masip, Josep, Mebazaa, Alexandre, Nikolaou, Maria, Ostadal, Petr, Põder, Pentti, Pollesello, Piero, Polyzogopoulou, Eftihia, Pölzl, Gerhard, Tschope, Carsten, Varpula, Marjut, von Lewinski, Dirk, Vrtovec, Bojan, Yilmaz, Mehmet Birhan, Zima, Endre, and Parissis, John

Abstract

Inotropes aim at increasing cardiac output by enhancing cardiac contractility. They constitute the third pharmacological pillar in the treatment of patients with decompensated heart failure, the other two being diuretics and vasodilators. Three classes of parenterally administered inotropes are currently indicated for decompensated heart failure, (i) the beta adrenergic agonists, including dopamine and dobutamine and also the catecholamines epinephrine and norepinephrine, (ii) the phosphodiesterase III inhibitor milrinone and (iii) the calcium sensitizer levosimendan. These three families of drugs share some pharmacologic traits, but differ profoundly in many of their pleiotropic effects. Identifying the patients in need of inotropic support and selecting the proper inotrope in each case remain challenging. The present consensus, derived by a panel meeting of experts from 21 countries, aims at addressing this very issue in the setting of both acute and advanced heart failure., SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2019

35. A pragmatic approach to the use of inotropes for the management of acute and advanced heart failure: An expert panel consensus

Author

Farmakis, Dimitrios, primary, Agostoni, Piergiuseppe, additional, Baholli, Loant, additional, Bautin, Andrei, additional, Comin-Colet, Josep, additional, Crespo-Leiro, Maria G., additional, Fedele, Francesco, additional, García-Pinilla, Jose Manuel, additional, Giannakoulas, George, additional, Grigioni, Francesco, additional, Gruchała, Marcin, additional, Gustafsson, Finn, additional, Harjola, Veli-Pekka, additional, Hasin, Tal, additional, Herpain, Antoine, additional, Iliodromitis, Efstathios K., additional, Karason, Kristjan, additional, Kivikko, Matti, additional, Liaudet, Lucas, additional, Ljubas-Maček, Jana, additional, Marini, Marco, additional, Masip, Josep, additional, Mebazaa, Alexandre, additional, Nikolaou, Maria, additional, Ostadal, Petr, additional, Põder, Pentti, additional, Pollesello, Piero, additional, Polyzogopoulou, Eftihia, additional, Pölzl, Gerhard, additional, Tschope, Carsten, additional, Varpula, Marjut, additional, von Lewinski, Dirk, additional, Vrtovec, Bojan, additional, Yilmaz, Mehmet Birhan, additional, Zima, Endre, additional, and Parissis, John, additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results